BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
VANCOUVER, BC, and MADISON, Wis. , April 10, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and SpayVac-for-Wildlife, Inc. (“SpayVac”) jointly announce that SpayVac has partnered with a world leader in the aquaculture space to field test single-injection, long-lasting immuno-contraceptive vaccines in farmed rainbow trout.
Related news for (BVAXF)
- BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
- BioVaxys Technology Corp. Granted Management Cease Trade Order
- Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth
- Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies
- BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT AND DEBT SETTLEMENT